Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
21
02
2020
pubmed:
7
6
2020
medline:
4
5
2021
entrez:
7
6
2020
Statut:
ppublish
Résumé
A paucity of data exists regarding inherited mutations associated with phyllodes tumors (PT); however, some are reported (TP53, BRCA1, and RB1). A PT diagnosis does not meet NCCN criteria for testing, including within Li-Fraumeni Syndrome (TP53). We sought to determine the prevalence of mutations associated with PT. We performed an 11-institution review of contemporary (2007-2017) PT practice. We recorded multigenerational family history and personal history of genetic testing. We identified patients meeting NCCN criteria for genetic evaluation. Logistic regression estimated the association of select covariates with likelihood of undergoing genetic testing. Of 550 PT patients, 59.8% (n = 329) had a close family history of cancer, and 34.0% (n = 112) had ≥ 3 family members affected. Only 6.2% (n = 34) underwent genetic testing, 38.2% (n = 13) of whom had only BRCA1/BRCA2 tested. Of 34 patients tested, 8.8% had a deleterious mutation (1 BRCA1, 2 TP53), and 5.9% had a BRCA2 VUS. Of women who had TP53 testing (N = 21), 9.5% had a mutation. Selection for testing was not associated with age (odds ratio [OR] 1.01, p = 0.55) or PT size (p = 0.12) but was associated with grade (malignant vs. benign: OR 9.17, 95% CI 3.97-21.18) and meeting NCCN criteria (OR 3.43, 95% confidence interval 1.70-6.94). Notably, an additional 86 (15.6%) patients met NCCN criteria but had no genetic testing. Very few women with PT undergo germline testing; however, in those selected for testing, a deleterious mutation was identified in ~ 10%. Multigene testing of a PT cohort would present an opportunity to discover the true incidence of germline mutations in PT patients.
Sections du résumé
BACKGROUND
BACKGROUND
A paucity of data exists regarding inherited mutations associated with phyllodes tumors (PT); however, some are reported (TP53, BRCA1, and RB1). A PT diagnosis does not meet NCCN criteria for testing, including within Li-Fraumeni Syndrome (TP53). We sought to determine the prevalence of mutations associated with PT.
METHODS
METHODS
We performed an 11-institution review of contemporary (2007-2017) PT practice. We recorded multigenerational family history and personal history of genetic testing. We identified patients meeting NCCN criteria for genetic evaluation. Logistic regression estimated the association of select covariates with likelihood of undergoing genetic testing.
RESULTS
RESULTS
Of 550 PT patients, 59.8% (n = 329) had a close family history of cancer, and 34.0% (n = 112) had ≥ 3 family members affected. Only 6.2% (n = 34) underwent genetic testing, 38.2% (n = 13) of whom had only BRCA1/BRCA2 tested. Of 34 patients tested, 8.8% had a deleterious mutation (1 BRCA1, 2 TP53), and 5.9% had a BRCA2 VUS. Of women who had TP53 testing (N = 21), 9.5% had a mutation. Selection for testing was not associated with age (odds ratio [OR] 1.01, p = 0.55) or PT size (p = 0.12) but was associated with grade (malignant vs. benign: OR 9.17, 95% CI 3.97-21.18) and meeting NCCN criteria (OR 3.43, 95% confidence interval 1.70-6.94). Notably, an additional 86 (15.6%) patients met NCCN criteria but had no genetic testing.
CONCLUSIONS
CONCLUSIONS
Very few women with PT undergo germline testing; however, in those selected for testing, a deleterious mutation was identified in ~ 10%. Multigene testing of a PT cohort would present an opportunity to discover the true incidence of germline mutations in PT patients.
Identifiants
pubmed: 32504368
doi: 10.1245/s10434-020-08480-z
pii: 10.1245/s10434-020-08480-z
pmc: PMC9945652
mid: NIHMS1871179
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3633-3640Subventions
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Références
Oncogene. 2001 Aug 2;20(34):4621-8
pubmed: 11498785
Virchows Arch. 2013 Jul;463(1):17-22
pubmed: 23794094
Am J Surg Pathol. 1998 Jan;22(1):64-9
pubmed: 9422317
Mol Clin Oncol. 2015 May;3(3):663-671
pubmed: 26137284
Cancer Genet Cytogenet. 2008 Jan 1;180(1):65-9
pubmed: 18068537
Cancer Genet Cytogenet. 2007 Jul 1;176(1):76-9
pubmed: 17574969
Medicine (Baltimore). 2017 Nov;96(46):e8552
pubmed: 29145261
J Clin Oncol. 2014 Jul 20;32(21):2217-23
pubmed: 24752044
Br J Cancer. 2000 Jun;82(12):1932-7
pubmed: 10864200
Clin Breast Cancer. 2012 Oct;12(5):373-7
pubmed: 22981939
Arch Pathol Lab Med. 2016 Jul;140(7):665-71
pubmed: 27362571
Ann Surg Oncol. 2015 Sep;22(9):2912-8
pubmed: 25652050
Cancer. 2006 Nov 1;107(9):2127-33
pubmed: 16998937
J Med Genet. 2009 Oct;46(10):689-93
pubmed: 19556618
Cancer. 1989 Jun 15;63(12):2532-6
pubmed: 2541890
Breast. 2017 Apr;32:26-32
pubmed: 28013032
Ann Surg Oncol. 2007 Oct;14(10):2961-70
pubmed: 17562113
J Clin Pathol. 2012 Jan;65(1):69-76
pubmed: 22049216
J Clin Oncol. 2019 Feb 20;37(6):453-460
pubmed: 30526229
World J Surg. 2006 Aug;30(8):1414-21
pubmed: 16865317
Ann Surg Oncol. 2009 Aug;16(8):2288-94
pubmed: 19424757
Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):492-500
pubmed: 17931796
Ann Surg Oncol. 2012 Aug;19(8):2612-7
pubmed: 22476816
J Clin Pathol. 2013 Jun;66(6):465-70
pubmed: 23533258
Diagn Mol Pathol. 1998 Dec;7(6):295-301
pubmed: 10207667
Am J Surg. 2006 Aug;192(2):141-7
pubmed: 16860620
Ann Surg Oncol. 2014 Apr;21(4):1222-30
pubmed: 24306659